moneyheap
BAYN.DE · Analysis updated Nov 6, 2026, 4:16 AM ET
Why is Bayer AG (BAYN.DE) stock moving?
Bayer AG continues to enjoy solid tailwinds following its strong Q3 2026 earnings release and upwards revision to full-year guidance. Group sales reached €10.053B with adjusted EBITDA climbing 6.9% to €1.615B, powered by accelerated commercial expansion in Pharmaceuticals where key growth drivers Nubeqa and Kerendia rose 58% and 65% respectively. This operational momentum enabled Bayer to raise its 2026 adjusted EBITDA target to €9.8B–€10.3B and divisional pharma margins to 25%–27%, more than compensating for patent roll-offs on legacy blockbusters. De-leveraging targets have improved alongside an upgraded free cash flow projection of -€1.5B to -€0.5B and year-end net debt expected between €28B–€29B. Crucially, anticipated judicial approval for the $7.25B glyphosate class settlement before Christmas offers decisive containment of historical litigation overhangs.
News behind the analysis
- Bayer raises 2026 profit outlook on pharmaceuticals strength in Q3Bayer raised its full-year 2026 adjusted EBITDA guidance to €9.8B–€10.3B after Q3 divisional pharma sales rose to €4.68B, beating analyst consensus.
- Bayer Q3 2026 results: Pharma momentum drives full-year outlook upgradeGroup sales reached €10.053B and adjusted EBITDA rose 6.9% to €1.615B, prompting upgraded full-year free cash flow and net debt targets.
- Bayer's pharma unit hits turning point as Nubeqa and Kerendia surgeQ3 Nubeqa revenue surged 58% to €998M while Kerendia rose 65% to €374M, offsetting patent expiration headwinds on mature medicines.
- Roundup settlement expected before Christmas, Bayer CEO saysCEO Bill Anderson expects judicial approval on the $7.25B glyphosate class settlement in Missouri court before Christmas, removing major legal overhang.
- Bayer Q3 2026 Earnings Call: Guidance raised across key metricsManagement reduced year-end net debt projections to €28B–€29B and narrowed negative free cash flow guidance following Apollo proceeds and operational cash gains.
- Bayer raises 2026 outlook as Nubeqa and Kerendia drive Pharmaceuticals recoveryPharma divisional EBITDA margin forecast was lifted to 25%–27% on blockbuster strength and strategic pipeline progress.